Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Pharmaceutical care for adult asthma patients: A controlled intervention one-year follow-up study.

Khdour MR, Elyan SO, Hallak HO, Jarab AS, Mukattash TL, Astal A.

Basic Clin Pharmacol Toxicol. 2019 Oct 19. doi: 10.1111/bcpt.13344. [Epub ahead of print]

PMID:
31628887
2.

TV-1380 attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces the formation of cocaethylene.

Shemesh-Darvish L, Shinar D, Hallak H, Gross A, Rosenstock M.

Drug Alcohol Depend. 2018 Jul 1;188:295-303. doi: 10.1016/j.drugalcdep.2018.01.033. Epub 2018 Mar 26.

PMID:
29807217
3.

Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro.

Czerwiński M, Amunom I, Piryatinsky V, Hallak H, Sahly Y, Bar-Ilan O, Bolliger P, Bassan M.

Pharmacol Res Perspect. 2018 Apr 16;6(3):e00397. doi: 10.1002/prp2.397. eCollection 2018 Jun.

4.

Impact of antimicrobial stewardship programme on hospitalized patients at the intensive care unit: a prospective audit and feedback study.

Khdour MR, Hallak HO, Aldeyab MA, Nasif MA, Khalili AM, Dallashi AA, Khofash MB, Scott MG.

Br J Clin Pharmacol. 2018 Apr;84(4):708-715. doi: 10.1111/bcp.13486. Epub 2018 Jan 23.

5.

Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.

Rabinovich-Guilatt L, Steiner L, Hallak H, Pastino G, Muglia P, Spiegelstein O.

Br J Clin Pharmacol. 2017 Oct;83(10):2214-2224. doi: 10.1111/bcp.13317. Epub 2017 Jun 21.

6.

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.

Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S, Wilson DS.

PLoS One. 2016 Sep 9;11(9):e0162472. doi: 10.1371/journal.pone.0162472. eCollection 2016.

7.

Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.

Ashkenazi N, Rosenstock M, Hallak H, Bassan M, Rasamoelisolo M, Leuschner J, Shinar D.

Growth Horm IGF Res. 2016 Oct - Dec;30-31:16-21. doi: 10.1016/j.ghir.2016.08.001. Epub 2016 Aug 3.

PMID:
27552669
8.

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak O, Hallak H, Chiang N, Gyaw S.

Drug Alcohol Depend. 2016 Sep 1;166:13-20. doi: 10.1016/j.drugalcdep.2016.05.019. Epub 2016 May 28.

9.

Comparison of an Atomic Model and Its Cryo-EM Image at the Central Axis of a Helix.

He J, Zeil S, Hallak H, McKaig K, Kovacs J, Wriggers W.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2015 Nov;2015:1253-1259.

10.

Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O.

J Clin Psychopharmacol. 2015 Aug;35(4):396-405. doi: 10.1097/JCP.0000000000000347. Erratum in: J Clin Psychopharmacol. 2016 Oct;36(5):537. Gilgun, Yossi [corrected to Gilgun-Serki, Yossi].

PMID:
26082975
11.
12.

Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.

Karaman R, Ghareeb H, Dajani KK, Scrano L, Hallak H, Abu-Lafi S, Mecca G, Bufo SA.

J Comput Aided Mol Des. 2013 Jul;27(7):615-35. doi: 10.1007/s10822-013-9666-2. Epub 2013 Jul 24.

PMID:
23881217
13.

Prevalence, awareness, treatment and control of hypertension in the Palestinian population.

Khdour MR, Hallak HO, Shaeen M, Jarab AS, Al-Shahed QN.

J Hum Hypertens. 2013 Oct;27(10):623-8. doi: 10.1038/jhh.2013.26. Epub 2013 Apr 11.

PMID:
23575447
14.

Patterns of NSAIDs use in Palestinian mid-territories: a prospective study of ambulatory patients in outpatient pharmacies.

Khdour MR, Hallak HO, Hejaz H, Shaeen M, Dweib M.

Curr Clin Pharmacol. 2014 Feb;9(1):10-6.

PMID:
23343016
15.

Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis--a computational approach.

Karaman R, Dokmak G, Bader M, Hallak H, Khamis M, Scrano L, Bufo SA.

J Mol Model. 2013 Jan;19(1):439-52. doi: 10.1007/s00894-012-1554-5. Epub 2012 Sep 2.

PMID:
22940872
16.

Identification of drug-related problems: a prospective study in two general hospitals.

Khdour MR, Jarab AS, Adas HO, Samaro EZ, Mukattash TL, Hallak HO.

Curr Clin Pharmacol. 2012 Nov;7(4):276-81.

PMID:
22794158
17.

Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys.

Schindler CW, Justinova Z, Lafleur D, Woods D, Roschke V, Hallak H, Sklair-Tavron L, Redhi GH, Yasar S, Bergman J, Goldberg SR.

Addict Biol. 2013 Jan;18(1):30-9. doi: 10.1111/j.1369-1600.2011.00424.x. Epub 2012 Jan 20.

18.

Societal perspectives on community pharmacy services in West Bank - Palestine.

Khdour MR, Hallak HO.

Pharm Pract (Granada). 2012 Jan;10(1):17-24. Epub 2012 Mar 31.

19.

Computer-assisted design for atenolol prodrugs for the use in aqueous formulations.

Karaman R, Dajani K, Hallak H.

J Mol Model. 2012 Apr;18(4):1523-40. doi: 10.1007/s00894-011-1180-7. Epub 2011 Jul 23.

PMID:
21785934
20.

Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine.

Khdour MR, Hallak HO, Alayasa KS, AlShahed QN, Hawwa AF, McElnay JC.

Int J Clin Pharm. 2011 Aug;33(4):650-5. doi: 10.1007/s11096-011-9520-3. Epub 2011 May 13.

PMID:
21567279
21.

Computer-assisted design of pro-drugs for antimalarial atovaquone.

Karaman R, Hallak H.

Chem Biol Drug Des. 2010 Oct;76(4):350-60. doi: 10.1111/j.1747-0285.2010.01018.x. Epub 2010 Aug 20.

PMID:
20731669
22.

ALS and mercury intoxication: a relationship?

Praline J, Guennoc AM, Limousin N, Hallak H, de Toffol B, Corcia P.

Clin Neurol Neurosurg. 2007 Dec;109(10):880-3. Epub 2007 Aug 23.

PMID:
17719172
23.

Inhibition of insulin-like growth factor I receptor tyrosine kinase by ethanol.

Rubin R, Harrison R, Chen XF, Corzitotto J, Hoek JB, Hallak H.

Biochem Pharmacol. 2004 Nov 15;68(10):2009-17.

PMID:
15476672
24.

Ethanol inhibits palmitoylation of G protein G alpha(s).

Hallak H, Rubin R.

J Neurochem. 2004 May;89(4):919-27.

25.

Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.

Stoner CL, Cleton A, Johnson K, Oh DM, Hallak H, Brodfuehrer J, Surendran N, Han HK.

Int J Pharm. 2004 Jan 9;269(1):241-9.

PMID:
14698595
26.

Determination of hydroxyproline in plasma and tissue using electrospray mass spectrometry.

Kindt E, Gueneva-Boucheva K, Rekhter MD, Humphries J, Hallak H.

J Pharm Biomed Anal. 2003 Dec 4;33(5):1081-92.

PMID:
14656599
27.

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.

PMID:
12907464
28.

[Isolated angiitis of the central nervous system. Report of two cases and review of the literature].

Hallak H, Fressinaud C, Emile J.

Rev Neurol (Paris). 2002 Nov;158(11):1071-81. Review. French.

PMID:
12451339
29.

Epidermal growth factor-induced activation of the insulin-like growth factor I receptor in rat hepatocytes.

Hallak H, Moehren G, Tang J, Kaou M, Addas M, Hoek JB, Rubin R.

Hepatology. 2002 Dec;36(6):1509-18.

PMID:
12447877
30.

Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors.

Böhme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD.

J Med Chem. 2002 Jul 4;45(14):3094-102. Erratum in: J Med Chem 2002 Oct 10;45(21):4800.

PMID:
12086495
31.

Molecular sieving and mass spectroscopy reveal enhanced collagen degradation in rabbit atheroma.

Chen J, Kindt E, Hallak H, Peterson JT, Rosebury WS, Hubbel AM, Bocan TM, Rekhter MD.

Atherosclerosis. 2001 Dec;159(2):289-95.

PMID:
11730808
32.

Inhibition of insulin-like growth factor-I signaling by ethanol in neuronal cells.

Hallak H, Seiler AE, Green JS, Henderson A, Ross BN, Rubin R.

Alcohol Clin Exp Res. 2001 Jul;25(7):1058-64.

PMID:
11505033
33.

Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist.

Albassam MA, Metz AL, Potoczak RE, Gallagher KP, Haleen S, Hallak H, McGuire EJ.

Toxicol Pathol. 2001 May-Jun;29(3):277-84.

PMID:
11442013
34.

Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.

Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG.

Circulation. 2001 May 8;103(18):2303-9.

PMID:
11342481
36.

Quantitative method for biomarkers of collagen degradation using liquid chromatography tandem mass spectrometry.

Kindt E, Rossi DT, Gueneva-Boucheva K, Hallak H.

Anal Biochem. 2000 Jul 15;283(1):71-6.

PMID:
10929810
37.

Hypercholesterolemia causes mechanical weakening of rabbit atheroma : local collagen loss as a prerequisite of plaque rupture.

Rekhter MD, Hicks GW, Brammer DW, Hallak H, Kindt E, Chen J, Rosebury WS, Anderson MK, Kuipers PJ, Ryan MJ.

Circ Res. 2000 Jan 7-21;86(1):101-8.

PMID:
10625311
38.

Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.

O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H.

J Med Chem. 2000 Jan 27;43(2):156-66.

PMID:
10649971
39.
40.

Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.

McElmurray JH 3rd, Mukherjee R, New RB, Sampson AC, King MK, Hendrick JW, Goldberg A, Peterson TJ, Hallak H, Zile MR, Spinale FG.

J Pharmacol Exp Ther. 1999 Nov;291(2):799-811.

PMID:
10525103
41.

Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.

Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR.

Circ Res. 1999 Aug 20;85(4):364-76.

PMID:
10455065
42.

Prevention of vasospasm after subarachnoid hemorrhage in dogs by continuous intravenous infusion of PD156707.

Macdonald RL, Johns L, Lin G, Marton LS, Hallak H, Marcoux F, Kowalczuk A.

Neurol Med Chir (Tokyo). 1998;38 Suppl:138-45.

43.

Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist.

Albassam MA, Metz AL, Gragtmans NJ, King LM, Macallum GE, Hallak H, McGuire EJ.

Toxicol Pathol. 1999 Mar-Apr;27(2):156-64.

PMID:
10207979
44.

Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase.

Mohr S, Hallak H, de Boitte A, Lapetina EG, Brüne B.

J Biol Chem. 1999 Apr 2;274(14):9427-30.

45.

Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow.

Petrossian E, Parry AJ, Reddy VM, Akkersdijk GP, McMullan DM, Thompson L, Hendricks-Munoz KD, Hallak H, Hanley FL, Fineman JR.

J Thorac Cardiovasc Surg. 1999 Feb;117(2):314-23.

46.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM.

J Med Chem. 1998 Oct 22;41(22):4365-77.

PMID:
9784112
47.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
48.

Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension.

Haleen S, Schroeder R, Walker D, Quenby-Brown E, Welch K, Hallak H, Uprichard A, Keiser J.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S331-5.

PMID:
9595473
49.

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA.

J Pharmacol Exp Ther. 1997 Dec;283(3):1433-44.

PMID:
9400019
50.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM.

J Med Chem. 1997 Jul 18;40(15):2296-303.

PMID:
9240345

Supplemental Content

Loading ...
Support Center